Ernexa Therapeutics Financials - Benzinga

SPY772.04 QQQ745.40 BTC/USD83,162.00−1.52%DIA517.72 GLD393.05 TLT79.38

Ernexa Therapeutics Inc

ERNANASDAQ

Trade with Public

Trade with Public

$3.42

-0.20-5.52%

At close: Sep 24, 5:00 PM EST

$3.44

-0.18-4.97%

Pre-Market: 3:00 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Ernexa Therapeutics Financials

Ernexa Therapeutics (ERNA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Nasdaq Jumps Over 400 Points; AutoNation Shares Surge Following Q4 Earnings

Avi Kapoor

PRO
Reported November 7, 2025: Ernexa Therapeutics Q3 EPS $(0.15) Up From $(73.70) YoY

Ernexa Therapeutics (NASDAQ:ERNA) reported quarterly losses of $(0.15) per share. This is a 99.8 percent increase over losses of $(73.70) per share from the same period last year.

Benzinga Newsdesk

Eterna Therapeutics Q4 EPS $(1.24) May Not Compare To $(2.40) Estimate

Eterna Therapeutics (NASDAQ:ERNA) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(2.40) by 48.33 percent. This is a 61.25 percent increase over losses of $(3.20) per share

Michael Horton